7 analysts have shared their evaluations of NovoCure (NASDAQ:NVCR) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 0 | 2 | 5 | 0 | 0 |
Last 30D | 0 | 0 | 1 | 0 | 0 |
1M Ago | 0 | 0 | 0 | 0 | 0 |
2M Ago | 0 | 1 | 1 | 0 | 0 |
3M Ago | 0 | 1 | 3 | 0 | 0 |
Analysts have recently evaluated NovoCure and provided 12-month price targets. The average target is $25.29, accompanied by a high estimate of $42.00 and a low estimate of $17.00. This current average has decreased by 3.36% from the previous average price target of $26.17.
Deciphering Analyst Ratings: An In-Depth Analysis
A comprehensive examination of how financial experts perceive NovoCure is derived...
Login or create a forever free account to read this news
Sign up/Log in